Radar · Life Sciences in British Columbia
Best Life Sciences Companies in British Columbia, Canada
The 305 best Life Sciences companies in British Columbia, Canada in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Novelion Therapeutics.
By Riya SenguptaFinancials
305companies tracked
$3Bdisclosed funding
0unicorns
135have raised
FLIAR INTELLIGENCE · LIFE SCIENCES × BRITISH COLUMBIA
Our analysis of 50 Life Sciences companies
$27.5b in tracked funding; 76% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
76%cloud-native stacks
2025funding peak (by rounds)
2013median founding year
45median Fliar Index™
267kcombined LinkedIn audience
40%of audience held by top 3
5companies hiring publicly (12 mo)
Ranked: Best Life Sciences companies in British Columbia
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Novelion Therapeutics Developing therapeutics for individuals with rare diseases | $325M | 95 mo ago | 109 | 1981 | — | 11 patents Patents concentrated in health & consumer products | — |
| 2 | Virogin Biotech Developed of drugs for the treatment of cancer | $281M | 56 mo ago | 56 | 2015 | William Jia Co-Founder | 103 patents Engineered oncolytic viruses for targeted cancer immunotherapy and viral vector platforms | — |
| 3 | Kardium Developer of ablation device for atrial fibrillation 78Funding top 20%Patents top 25%Product top 25%Moat top 26% All 11 signals ▾Fundingtop 20% Patentstop 25% Producttop 25% Moattop 26% Innovationtop 27% Talenttop 28% Growthtop 35% Markettop 42% Techtop 42% Globalbottom 44% Newsbottom 20% Funding: Raised $221M across 5 rounds · 5 rounds over 16 yrs (0.3/yr) Patents: 446 patents matched (strict assignee match) · 131 filings since 2022 vs 180 in 2017-21 rank vs industry peers · Fliar Intelligence Index 78/100 | $221M | 11 mo ago | 230 | 2007 | Sam Lichtenstein Co-Founder | 446 patents Cardiac electrophysiology: catheter navigation, high‑density mapping, and pulsed‑field ablation systems | 1 award |
| 4 | Zymeworks Developer of bi-specific antibodies & antibody-drug conjugates to treat cancer | $146M | 29 mo ago | 277 277 → 271 (-2%) | 2003 | — | 1,015 patents Design and production of bispecific/trispecific recombinant antibody therapeutics targeting cancer antigens. | — |
| 5 | Abdera Therapeutics Provider of therapeutics for cancer treatment. | $142M | 37 mo ago | 20 | 2020 | Adam Judge Co-Founder | 9 patents DLL3-targeted radioimmunoconjugates and chelator technologies for cancer radionuclide therapy | — |
| 6 | Neuromed Pharmaceuticals Provider of calcium channel blockers for pain treatment | $126M | 225 mo ago | — | 1998 | Peter Beltran CEO | 103 patents Novel small‑molecule calcium channel blocker compounds for cardiovascular therapeutics | — |
| 7 | Neovasc Developer of devices to treat cardiovascular conditions | $119M | 50 mo ago | 63 | 2001 | — | 18 patents Transcatheter mitral valve replacement devices and delivery system technologies | — |
| 8 | Abcellera Biologics AI-enabled platform for antibodies discovery | $115M | 60 mo ago | 560 | 2012 | — | 50 patents Therapeutic antibody discovery using transgenic rodent platforms and computational affinity modeling | 1 partnership |
| 9 | Lungpacer Developer of a neurostimulation-based pacer for diaphragm strength 50Funding top 23%Innovation top 27%Moat top 31%Product top 35% All 8 signals ▾Fundingtop 23% Innovationtop 27% Moattop 31% Producttop 35% Techtop 43% Talentbottom 49% Globalbottom 40% Marketbottom 28% Funding: Raised $111M across 8 rounds · 8 rounds over 13 yrs (0.6/yr) Innovation: 3 product lines · Deep-tech classification: Tech Hardware rank vs industry peers · Fliar Intelligence Index 50/100 | $111M | 1 mo ago | — | 2009 | Doug Evans President & CEO | — | 3 launchs |
| 10 | The Valens Company Developer of cannabinoid based products | $89M | 57 mo ago | 445 | 2012 | Tyler Robson Chief Executive Officer | — | — |
| 11 | Xenon Pharmaceuticals Developer of small molecule drugs against rare channelopathies | $86M | 237 mo ago | 19 | 2000 | Simon Pimstone CEO | 1,484 patents Design and synthesis of heteroaryl amine drug candidates and prodrugs for CNS therapies | 3 awards |
| 12 | Alpha-9 Theranostics Developer of molecules for solid and hematologic malignancies | $84M | 42 mo ago | 24 | 2019 | Ian McBeath CEO | 6 patents Radiopharmaceuticals targeting PSMA and CXCR4 for cancer imaging and therapy | — |
| 13 | Angle Developer of cancer cell capture and analysis equipment | $81M | 47 mo ago | 176 | 1994 | — | — | — |
| 14 | ProNAi Therapeutics Developer of DNA-based gene therapies for cancer and other genetic diseases | $77M | 145 mo ago | — | 2004 | Nick Glover President and CEO | — | — |
| 15 | Aquinox Pharma Small molecule targeting PI3K pathway. | $71M | 158 mo ago | — | 2004 | — | — | — |
| 16 | Gandeeva Provider of precision medicine company leveraging cryo-EM and machine learning for drug discovery | $40M | 52 mo ago | 35 | 2017 | Sriram Subramaniam Founder & CEO | — | — |
| 17 | Affinor Growers Developer of vertical farming technology and supplier of turnkey facilities | $38M | 44 mo ago | — | 1996 | Nick Brusatore Founder & CEO | 17 patents Automated vertical farming towers for high‑density horticulture and controlled‑environment agriculture | — |
| 18 | SaNOtize Developer of a nitric oxide-based solution to treat infections | $34M | 45 mo ago | 15 | 2017 | Gilly Regev Co-Founder | — | — |
| 19 | Qu Biologics Developing Site Specific Immunomodulators that aim to reboot the body's immune system to treat cancer and… | $30M | 50 mo ago | 22 | 2007 | — | 80 patents Innate immune modulation for cell therapies, anti‑inflammatory and antimicrobial biologics | — |
| 20 | Fresh Prep Online platform to buy recipe box with pre-prepped ingredients 64Tech top 25%Market top 32%Growth top 37%Talent top 38% All 10 signals ▾Techtop 25% Markettop 32% Growthtop 37% Talenttop 38% Fundingtop 39% Moattop 41% Patentsbottom 43% Innovationbottom 39% Globalbottom 37% Newsbottom 21% Tech: 51 technologies across 6/8 capability areas · Cloud: Cloudflare Market: 431 employees (top 3% of Life Sciences) · Top-500,000 web property rank vs industry peers · Fliar Intelligence Index 64/100 | $28M | 11 mo ago | 431 | 2015 | Dhruv Sood Co-Founder & Co-CEO | 5 patents Reusable insulated containers for meal kit delivery and food packaging | 1 award |
| 21 | AlphaCognition Developer of therapeutics to treat neurological disease | $26M | 20 mo ago | 4 | 2000 | Michael Mcfadden CEO | — | — |
| 22 | Zucara Therapeutics Developing a long-term therapeutic approach to prevent hypoglycemia in patients with diabetes 29Product top 35%Funding top 36%Innovation top 38%Moat top 39% All 8 signals ▾Producttop 35% Fundingtop 36% Innovationtop 38% Moattop 39% Talentbottom 49% Globalbottom 36% Techbottom 35% Marketbottom 27% Product: 3 distinct product lines · Company stage: Series B Funding: Raised $25.4M across 7 rounds · 7 rounds over 11 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 29/100 | $25M | 16 mo ago | 12 | 2015 | Richard Liggins Co Founder & Chief Scientific Officer | — | — |
| 23 | Precision Nanosystems Manufactures instruments, kits, and reagents for nanomedicine development | $25M | 45 mo ago | 150 | 2010 | — | — | — |
| 24 | NervGen Developer of therapeutics for the treatment of nerve damage | $22M | 44 mo ago | 11 | 2016 | Harold Punnett Director | — | — |
| 25 | ImmunoPrecise Antibodies CDMO focused on antibody discovery and pre-clinical services | $18M | 23 mo ago | 80 | 1989 | Chris Buyse Board of Directors | 5 patents Monoclonal antibody production and diagnostics for estrogen receptors and muscular dystrophy biomarkers | — |
| 26 | Bionxt Developer of drug formulations and delivery systems for various diseases 37News top 36%Funding top 38%Partners top 40%Patents top 46% All 11 signals ▾Newstop 36% Fundingtop 38% Partnerstop 40% Patentstop 46% Growthtop 47% Talenttop 49% Moatbottom 49% Innovationbottom 46% Techbottom 43% Marketbottom 39% Globalbottom 38% News: 9 BI events in 12 mo (of 28 tracked, 7 types) · -36% YoY Funding: Raised $12.6M across 11 rounds · 11 rounds over 4 yrs (2.8/yr) rank vs industry peers · Fliar Intelligence Index 37/100 | $13M | 15 mo ago | 25 | 2018 | Hugh Rogers CEO | 7 patents Novel psilocin prodrugs and enteric drug delivery formulations for pharmaceutical applications. | 1 partnership |
| 27 | Reverb Therapeutics Developer of treatments for cancer and other diseases | $12M | 15 mo ago | — | 2022 | Surjit Dixit Co-Founder | — | — |
| 28 | Lexaria Bioscience Developer of drug delivery technology designed to improve drug absorption | $8M | 32 mo ago | 6 | 2004 | Chris Bunka CEO & Chairman | — | 1 launch |
| 29 | Rakovina Therapeutics Developer of precision medicine to kill cancer cells 27Funding top 37%Patents top 40%Tech top 46%Growth top 47% All 9 signals ▾Fundingtop 37% Patentstop 40% Techtop 46% Growthtop 47% Newstop 48% Moatbottom 49% Innovationbottom 48% Globalbottom 35% Marketbottom 18% Funding: Raised $7.9M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Patents: 9 patents matched (strict assignee match) · 8 filings since 2022 vs 1 in 2017-21 rank vs industry peers · Fliar Intelligence Index 27/100 | $8M | 13 mo ago | 6 | 2020 | — | 9 patents Dual PARP‑HDAC inhibitor therapeutics for DNA‑repair and epigenetic cancer treatment | — |
| 30 | Promino Nutraceutical company specializing in protein drinks | $8M | 14 mo ago | — | 2021 | Arun Yagnick Managing Director | — | — |
| 31 | Sirona Biochem Developer of therapeutics for the treatment of skincare | $7M | 13 mo ago | 11 | 2006 | Howard Verrico CEO | — | — |
| 32 | Conexeu Sciences Developer of products for skin restoration and wound care 42Talent top 45%Funding top 47%Global bottom 25% All 3 signals ▾Talenttop 45% Fundingtop 47% Globalbottom 25% Talent: 2 named leaders on record Funding: Raised $6.9M across 5 rounds · 5 rounds over 1 yrs (5.0/yr) rank vs industry peers · Fliar Intelligence Index 42/100 | $7M | 3 mo ago | — | 2023 | Ryan Hartwell Co-Founder & CEO | — | 1 launch · 1 expansion |
| 33 | Biomark Diagnostics Provider of metabolomics-based diagnostics for cancer | $5M | 14 mo ago | 6 | 2007 | — | — | — |
| 34 | Molecular You Developer of personalized multi-omic digital health platform 53Talent top 28%Innovation top 31%Patents top 31%Moat top 32% All 9 signals ▾Talenttop 28% Innovationtop 31% Patentstop 31% Moattop 32% Techtop 37% Fundingtop 47% Productbottom 48% Globalbottom 36% Marketbottom 33% Talent: Analyst team rating 4/5 Innovation: 24 patents (top 39% of patent-holders) · 19 filings since 2022 vs 5 in 2017-21 rank vs industry peers · Fliar Intelligence Index 53/100 | $5M | 9 mo ago | 28 | 2014 | — | 24 patents Molecular diagnostics and personalized therapeutics for pancreatic cancer, Alzheimer's, autism. | 1 partnership |
| 35 | Renaissance BioScience Developer of bioengineering technology for agriculture, food, health, and industrial markets | $5M | 28 mo ago | 22 | 2013 | John Husnik Co-Founder & CEO | 30 patents Engineered yeast for RNA delivery and asparagine reduction to lower acrylamide in foods | 1 job opening |
| 36 | Mesentech Developer of therapies for treating bone disorders | $4M | 17 mo ago | 13 | 2016 | Ian McBeath Founder & Co-CEO | — | — |
| 37 | ViewsML AI-powered platform for drug development and companion diagnostics 21AI top 45%Funding top 46%Talent bottom 49%Global bottom 36% All 5 signals ▾AItop 45% Fundingtop 46% Talentbottom 49% Globalbottom 36% Marketbottom 21% AI: Product described with: ai-powered Funding: Raised $3.6M across 1 rounds · 1 rounds over 2 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 21/100 | $4M | 1 mo ago | 8 | 2022 | Kenneth To CEO | — | 1 award |
| 38 | Variational AI based platform for small-molecule drug discovery | $4M | 15 mo ago | 10 | 2019 | Handol Kim Co-Founder & CEO | 2 patents Design and synthesis of protease inhibitor therapeutics for disease treatment | 2 awards |
| 39 | PreveCeutical Developer of peptide based therapuetics for cancer treatment | $2M | 12 mo ago | 7 | 2015 | Mak Jawadekar Co-Founder | — | — |
| 40 | XYON Provider of prescription treatments and hair care products for hair loss | $2M | 14 mo ago | — | 2021 | Simon Pimstone Founder & CEO | — | — |
| 41 | Andira Digital pharmacotherapeutic platform for providers 21Funding top 50%Talent bottom 49%Market bottom 37%Global bottom 29% All 4 signals ▾Fundingtop 50% Talentbottom 49% Marketbottom 37% Globalbottom 29% Funding: Raised $1.4M across 5 rounds · 5 rounds over 4 yrs (1.2/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 21/100 | $1M | 3 mo ago | — | 2020 | Dana Lambert Chief Executive Officer | — | — |
| 42 | Allied Health Medical cannabis supplier delivering pharmaceutical-grade solutions worldwide 11Funding top 44%Talent bottom 49%Market bottom 34%Growth bottom 32% All 6 signals ▾Fundingtop 44% Talentbottom 49% Marketbottom 34% Growthbottom 32% Globalbottom 30% Fin. healthbottom 15% Funding: Raised $1.4M across 9 rounds · 9 rounds over 7 yrs (1.3/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 11/100 | $1M | 19 mo ago | 165 | 2019 | Calum Hughes Founder & CEO | — | — |
| 43 | VoxCell BioInnovation Manufacturer of 3D bioprinters | $1M | 15 mo ago | 15 | 2020 | Andrew Garland Co-Founder & CTO | 7 patents Patents concentrated in health & consumer products | 1 partnership |
| 44 | Vesalius Cardiovascular Biomedical devices for the treatment of mitral valve regurgitation | $1M | 10 mo ago | 12 | 2016 | Peter Skarsgard Co-Founder | 52 patents Minimally invasive mitral valve repair devices and tissue anchoring systems | — |
| 45 | Lobe Sciences Developer of small-molecule-based therapeutic solutions for the treatment of neurological disorders 50Growth top 15%News top 25%Moat top 32%Patents top 35% All 10 signals ▾Growthtop 15% Newstop 25% Moattop 32% Patentstop 35% Innovationtop 41% Talenttop 44% Fundingtop 47% Techbottom 46% Globalbottom 33% Marketbottom 25% Growth: Fresh capital in last 24 mo News: 8 BI events in 12 mo (of 14 tracked, 3 types) · +700% YoY rank vs industry peers · Fliar Intelligence Index 50/100 | $942K | 1 mo ago | — | 2018 | Tom Baird CEO | 25 patents Stable psilocin salt formulations for psychedelic drug development and therapeutic use. | — |
| 46 | Replicel Developer of cell therapy products focused on aesthetics and orthopedics | $867K | 18 mo ago | 1 | 2010 | — | — | — |
| 47 | Ondine Biomedical Developer of anti-infective therapies for a broad spectrum of bacterial, viral and fungal infections | $798K | 16 mo ago | 38 | 1999 | Carolyn Cross Founder & CEO | — | 1 award |
| 48 | Novation Pharmaceuticals Developer of small molecules to modulate intracellular messenger RNA using a proprietary discovery platform | $626K | 15 mo ago | — | 1999 | Dominique Cheneval President and Co-Founder | 21 patents Novel benzopyran therapeutics and mRNA‑stability screening assays for drug discovery | — |
| 49 | eupraxia pharmaceuticals Eupraxia is a clinical-stage biotech company developing locally delivered, extended-release alternatives to… | $473K | 19 mo ago | 21 | 2012 | — | 99 patents Controlled‑release injectable drug formulations and crystal engineering for targeted anti‑inflammatory therapy | 1 job opening |
| 50 | Burcon Provider of plant protein based health drinks and products 48Product top 14%Growth top 25%News top 25%Innovation top 34% All 9 signals ▾Producttop 14% Growthtop 25% Newstop 25% Innovationtop 34% Talenttop 43% Fundingtop 49% Techbottom 39% Marketbottom 31% Globalbottom 29% Product: 12 distinct product lines · Company stage: Public Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 48/100 | $164K | 5 mo ago | 26 | 1998 | Allan Yap Ex-CEO | — | — |
Top 12 Life Sciences companies in British Columbia
#1
Series B · Vancouver, British Columbia · founded 2009$111.4Mraised▾
Series B · Vancouver, British Columbia · founded 2009
Developer of a neurostimulation-based pacer for diaphragm strength. It provides lungpacer system that uses a minimally invasive, transvascular nerve stimulation technology to activate the diaphragm. Its electrodes are intravenously inserted into the lungs to rhythmically activate the diaphragm through neurostimulation to restore negative pressure ventilation. The pacing therapy is used to prevent or reverse diaphragm muscle-disuse atrophy and maintain diaphragmatic endurance.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Funding
top 23%Innovation
top 27%Moat
top 31%Product
top 35%Tech
top 43%Talent
bottom 49%Funding: Raised $111M across 8 rounds · 8 rounds over 13 yrs (0.6/yr) · Last round Series B (Apr 2026)
Innovation: 3 product lines · Deep-tech classification: Tech Hardware
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 9 curated direct competitors tracked
Audience (LinkedIn): 4k LinkedIn followers
Activity (LinkedIn): 3 product launches announced in 12 mo
Funding rounds
- Apr 2026Series B$12M
- Mar 2025Series B$10M
- Apr 2022Series B$20M
- Jan 2021Grant (prize money)$5.4M
Founders & team
Investors
Canadian Institutes of Health Research, Military Health, KCK MedTech, Keiretsu Capital, Valiance Asset Management, New Enterprise Associates
Tech stack
Apache Http ServerApple Icloud MailCloudflareCloudflare Bot ManagementCookieyesCore-Js
#2
Series C · Burnaby, British Columbia · founded 2007 · 230 employees$221.4Mraised▾
Series C · Burnaby, British Columbia · founded 2007 · 230 employees
Kardium is developing the Globe mapping and ablation system. It's an investigational medical device, used in the diagnosis and treatment of atrial fibrillation. It provides mapping, stimulation, and RF ablation of cardiac tissue.
Fliar Intelligence Index™ 78how this company ranks against its industry peers
Funding
top 20%Patents
top 25%Product
top 25%Moat
top 26%Innovation
top 27%Talent
top 28%Funding: Raised $221M across 5 rounds · 5 rounds over 16 yrs (0.3/yr) · Last round Series C (Jul 2025)
Patents: 446 patents matched (strict assignee match) · 131 filings since 2022 vs 180 in 2017-21 · Latest publication 2026
Product: 6 distinct product lines · Company stage: Series C
Audience (LinkedIn): 25k LinkedIn followers — 9.6% of this cohort's audience · 152 engagements/post (1.7× cohort median)
Activity (LinkedIn): 1 awards announced in 12 mo
Funding rounds
- Jul 2025Series C$250M
- Jun 2024Series B$104M
- Dec 2020Series B$116.3M
- Feb 2019Series A—
Founders & team
Investors
T. Rowe Price, Fidelity Investments, Durable Capital Partners, Janus Henderson Investors, Qatar Investment Authority, Piper Sandler
Tech stack
Backbone.JsCloudflareCloudflare Bot ManagementCloudflare Browser InsightsCookie NoticeCore-Js
#3
Seed · Vancouver, British Columbia · founded 2023$6.9Mraised▾
Seed · Vancouver, British Columbia · founded 2023
Developer of products for skin restoration and wound care. The company uses CXU Scaffold technology that enhances tissue regeneration for wound healing and superior epithelialization.
Fliar Intelligence Index™ 42how this company ranks against its industry peers
Talent
top 45%Funding
top 47%Global
bottom 25%Talent: 2 named leaders on record
Funding: Raised $6.9M across 5 rounds · 5 rounds over 1 yrs (5.0/yr) · Last round Seed (Mar 2026)
Global: Single-market focus (Canada)
Audience (LinkedIn): 664 LinkedIn followers
Activity (LinkedIn): 1 product launches · 1 expansions announced in 12 mo
Funding rounds
- May 2026Seed$44.7K
- Mar 2026Seed$1.8M
- Jan 2026Seed$810K
- Oct 2025Seed$2.9M
Founders & team
#4
Seed · Vancouver, British Columbia · founded 2022 · 8 employees$3.6Mraised▾
Seed · Vancouver, British Columbia · founded 2022 · 8 employees
AI-powered platform for drug development and companion diagnostics. The company's key platform technology, Aion, virtualizes the IHC process to forecast biomarker expression spatially and increase efficiencies in drug discovery, as well as hasten patient selection in clinical trials.
Fliar Intelligence Index™ 21how this company ranks against its industry peers
AI
top 45%Funding
top 46%Talent
bottom 49%Global
bottom 36%Market
bottom 21%AI: Product described with: ai-powered
Funding: Raised $3.6M across 1 rounds · 1 rounds over 2 yrs (0.5/yr) · Last round Seed (Apr 2026)
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Audience (LinkedIn): 1k LinkedIn followers
Activity (LinkedIn): 1 awards announced in 12 mo
Funding rounds
- Apr 2026Seed$3.6M
- 2024Seed—
- 2024Seed—
Founders & team
Investors
PAX Momentum, RiSC Capital, Wittington Ventures, Continuum Health Ventures, Mayo Clinic, Debiopharm
#5
Series C · Vancouver, British Columbia · founded 2015 · 431 employees$27.8Mraised▾
Series C · Vancouver, British Columbia · founded 2015 · 431 employees
Fresh Prep is an online platform to buy recipe boxes with pre-prepped ingredients. Each recipe box contains the pre-prepared ingredients along with step-by-step instructions to prepare the meals. Claims that the meals can be prepared in under 30 minutes. Sources the ingredients from local suppliers.
Fliar Intelligence Index™ 64how this company ranks against its industry peers
Tech
top 25%Market
top 32%Growth
top 37%Talent
top 38%Funding
top 39%Moat
top 41%Tech: 51 technologies across 6/8 capability areas · Cloud: Cloudflare · Devops: Nginx
Market: 431 employees (top 3% of Life Sciences) · Top-500,000 web property
Growth: 1 acquisition/expansion move in 24 mo · Fresh capital in last 24 mo
Audience (LinkedIn): 10k LinkedIn followers — 3.8% of this cohort's audience
Activity (LinkedIn): 1 partnerships · 4 awards (incl. Chef Craig Wong of Toronto's Patois) announced in 12 mo
Funding rounds
- Jul 2025Series C—
- Sep 2021Series B$16.7M
- May 2020Series A$5M
- Apr 2020Series A$1.9M
Founders & team
Investors
Renewal Funds, Yellow Point Equity Partners, First West Credit Union, SEMCAP
Tech stack
ActivecampaignAutoptimizeBootstrapCloudflareCloudflare Bot ManagementContentful
#6
Seed · Vancouver, British Columbia · founded 2020$1.4Mraised▾
Seed · Vancouver, British Columbia · founded 2020
Digital pharmacotherapeutic platform for providers. It is a platform for the discovery and creation of natural chemicals with the potential for medicinal usage.
Fliar Intelligence Index™ 21how this company ranks against its industry peers
Funding
top 50%Talent
bottom 49%Market
bottom 37%Global
bottom 29%Funding: Raised $1.4M across 5 rounds · 5 rounds over 4 yrs (1.2/yr) · Last round Seed (Feb 2026)
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Audience (LinkedIn): 726 LinkedIn followers
Funding rounds
- Feb 2026Seed$152.4K
- Aug 2024Seed$809.9K
- Jun 2024Seed$18.3K
- Oct 2023Seed$212K
Founders & team
Investors
First Fund
#7
Public · Vancouver, British Columbia · founded 2018$942.3Kraised▾
Public · Vancouver, British Columbia · founded 2018
Developer of small-molecule-based therapeutic solutions for the treatment of neurological disorders. The company has developed psilocybin and N-Acetylcysteine drug for the treatment of mild traumatic brain injury & stress disorder. It has also developed devices to treat brain traumas.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Growth
top 15%News
top 25%Moat
top 32%Patents
top 35%Innovation
top 41%Talent
top 44%Growth: Fresh capital in last 24 mo
News: 8 BI events in 12 mo (of 14 tracked, 3 types) · +700% YoY · 1 high-value events (IPO/M&A/funding/contracts) in 12 mo
Moat: Editorial + unicorn rating 4/10 · IP moat: 25 patents
Audience (LinkedIn): 973 LinkedIn followers
Funding rounds
- Apr 2026Post IPO$693.4K
- Jul 2025Post IPO$248.8K
- Dec 2020Post IPO—
Founders & team
#8
Series B · Vancouver, British Columbia · founded 2015 · 12 employees$25.4Mraised▾
Series B · Vancouver, British Columbia · founded 2015 · 12 employees
Zucara Therapeutics, a spin-off of The Centre for Drug Research and Development (CDRD) and MaRS Innovation (MI), is developing a novel drug for the treatment of hypoglycemia associated with insulin therapy. Their lead candidate PRL-2903 works via the chronic receptor antagonism through which they block somatostatin type 2 (SSTR2) receptors on α-cells in the pancreas.
Fliar Intelligence Index™ 29how this company ranks against its industry peers
Product
top 35%Funding
top 36%Innovation
top 38%Moat
top 39%Talent
bottom 49%Global
bottom 36%Product: 3 distinct product lines · Company stage: Series B
Funding: Raised $25.4M across 7 rounds · 7 rounds over 11 yrs (0.6/yr) · Last round Series B (Feb 2025)
Innovation: 3 product lines
Audience (LinkedIn): 2k LinkedIn followers
Funding rounds
- Feb 2025Series B$5M
- Nov 2024Series B$20M
- May 2022Grant (prize money)—
- Nov 2020Grant (prize money)—
Founders & team
Investors
National Research Council Canada, Perceptive Advisors, Cdrd.ca, TIAP, JDRF, Accel-Rx
Tech stack
WordpressMysqlPhpThe Events CalendarContact Form 7Slider Revolution
#9
Public · Vancouver, British Columbia · founded 2018 · 25 employees$12.6Mraised▾
Public · Vancouver, British Columbia · founded 2018 · 25 employees
Developer of drug formulations and delivery systems for various diseases. The company focuses on developing precision transdermal and oral dissolvable drug delivery formulations, rapid, infectious disease, and oral health screening tests, and clinical evaluation of active pharmaceutical ingredients for neurological applications. The company's product include Vektor a drug formulation for efficient and affordable delivery of approved neurological medications.
Fliar Intelligence Index™ 37how this company ranks against its industry peers
News
top 36%Funding
top 38%Partners
top 40%Patents
top 46%Growth
top 47%Talent
top 49%News: 9 BI events in 12 mo (of 28 tracked, 7 types) · -36% YoY · 6 high-value events (IPO/M&A/funding/contracts) in 12 mo
Funding: Raised $12.6M across 11 rounds · 11 rounds over 4 yrs (2.8/yr) · Last round Post IPO (Feb 2025)
Partners: 2 contract events in 12 mo · Named contractor/client in 2 deals
Audience (LinkedIn): 584 LinkedIn followers
Activity (LinkedIn): 1 product launches · 2 partnerships (incl. BioNxt Solutions Inc.) announced in 12 mo
Funding rounds
- Feb 2025Post IPO$1.7M
- Jan 2025Post IPO$138.9K
- Jan 2025Post IPO$620.1K
- Jan 2025Post IPO$288.8K
Founders & team
Investors
Planet Ventures
Tech stack
Advanced Custom FieldsAmazon S3Amazon Web ServicesCookieyesElementorGodaddy
#10
Series A · Vancouver, British Columbia · founded 2014 · 28 employees$5Mraised▾
Series A · Vancouver, British Columbia · founded 2014 · 28 employees
Developer of personalized multi-omic digital health platform. and recommendations for health interventions by interpreting a person's genetic, metabolite, protein, and microbial molecular profiles. The company's platform is called MYHealthIntelligence, and it generates predictive and prescriptive health insights and personalized action plans covering various organs/health systems and diseases. The platform allows users to securely store, share, navigate and analyze their data on its cloud platform, and allows medical practitioners to create proactive and targeted plans.
Fliar Intelligence Index™ 53how this company ranks against its industry peers
Talent
top 28%Innovation
top 31%Patents
top 31%Moat
top 32%Tech
top 37%Funding
top 47%Talent: Analyst team rating 4/5
Innovation: 24 patents (top 39% of patent-holders) · 19 filings since 2022 vs 5 in 2017-21
Patents: 24 patents matched (strict assignee match) · 19 filings since 2022 vs 5 in 2017-21 · Latest publication 2026
Audience (LinkedIn): 3k LinkedIn followers
Activity (LinkedIn): 2 partnerships (incl. NPK Co., Ltd.) announced in 12 mo
Funding rounds
- Aug 2025Series A$5M
Investors
Voloridge, Dynamic Leap, Pointgrey Partners
Tech stack
Amazon S3Amazon Web ServicesApple Icloud MailApple PayBamboohrBootstrap
#11
Public · Vancouver, British Columbia · founded 2020 · 6 employees$7.9Mraised▾
Public · Vancouver, British Columbia · founded 2020 · 6 employees
Developer of precision medicine to kill cancer cells. The company has biomarker-driven, next-generation PARP-inhibitor therapeutics that include KT-2000, KT-3000, and KT-4000. It releases a DNA-damaging agent, which inhibits the DNA damage repair pathway and kills cancer cells.
Fliar Intelligence Index™ 27how this company ranks against its industry peers
Funding
top 37%Patents
top 40%Tech
top 46%Growth
top 47%News
top 48%Moat
bottom 49%Funding: Raised $7.9M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) · Last round Post IPO (May 2025)
Patents: 9 patents matched (strict assignee match) · 8 filings since 2022 vs 1 in 2017-21 · Latest publication 2025
Tech: 33 technologies across 3/8 capability areas · Cloud: Amazon S3, Amazon Web Services · Security: Cloudflare Bot Management, Http/3
Audience (LinkedIn): 2k LinkedIn followers
Funding rounds
- May 2025Post IPO$2.9M
- Jan 2025Post IPO$1.5M
- Dec 2024Post IPO$2.1M
- May 2024Post IPO$1.5M
Investors
National Research Council Canada, Mitacs, Red Thread Ventures, Planet Ventures
Tech stack
Amazon S3Amazon Web ServicesAstraCloudflareCloudflare Bot ManagementCloudflare Browser Insights
#12
Public · Vancouver, British Columbia · founded 2006 · 11 employees$7.4Mraised▾
Public · Vancouver, British Columbia · founded 2006 · 11 employees
Developer of therapeutics for the treatment of skincare. The company is developing anti-aging and anti-wrinkle molecule, TFC-1326, as GlycoProteMim to preserve and restore youthful skin and reverse aging.
Funding rounds
- Apr 2025Post IPO$2.2M
- Apr 2024Post IPO$97.8K
- Jul 2019Post IPO$1.1M
- Feb 2019Post IPO$1.8M
Founders & team
Investors
Jiangsu Wanbang Biochemical Pharmaceutical
Funding & investor landscape
$3Btotal disclosed funding
130companies funded
495disclosed rounds
4rounds last 90 days
Most active investors
Notable founders
Doug Evans
President & CEO · Lungpacer
Sam Lichtenstein
Co-Founder · Kardium
Dan Gelbart
Co-Founder · Kardium
Ryan Hartwell
Co-Founder & CEO · Conexeu Sciences
David Bogart
Co-Founder · Conexeu Sciences
Kenneth To
CEO · ViewsML
Dhruv Sood
Co-Founder & Co-CEO · Fresh Prep
Husein Rahemtulla
Co-Founder & COO · Fresh Prep
Dana Lambert
Chief Executive Officer · Andira
Tom Baird
CEO · Lobe Sciences
Richard Liggins
Co Founder & Chief Scientific Officer · Zucara Therapeutics
Hugh Rogers
CEO · Bionxt
Prism market signals · Canada · country-scoped Prism corpus, 188,258 docs
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH SIGNALS · Canada
How research on Biotechnology is moving in Canada
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 990 Canada-affiliated papers.
research sentiment over time
200820162026
enthusiastic · positive · guarded tone
Tone is overwhelmingly optimistic and intensifying — the enthusiastic (strongly-positive) share moved 39% → 44% across 2008–2026.
top research entities
- Ministry of Agriculture118
- Ministry of Education70
- University of Toronto61
- McGill University60
- Agriculture and Agri-Food Canada58
leading researchers
Davoud Torkamaneh · Maxime de Ronne · Vincent Lefebvre · Sylvie Deslauriers · Théo Devèze · Bernard R. Glick · Rotimi E. Aluko · Warren C. W. Chan
▲
Breakthroughs267 · 27%
▼ 31%→27% share
▼0.9× share momentum0 median citations82% since 2021mostly empirical
Gene-focused breakthrough research surged from 3 to 32 papers, with antibody and immune system topics newly emerging at 12 and 8 papers respectively.
rising sub-themes (early→recent)
- Gene3→32
- Mutant2→13
- Genome2→12
- Transcription factor2→11
- Transcription (linguistics)1→9
Newly emergingAntibody 0→12 · Immune system 0→8 · Mutation 0→7
Landmark In situ click chemistry generation of cyclooxygenase-2 inhibitors · 7,514 cites
◆
Advancements374 · 38%
▲ 31%→40% share
▲1.3× share momentum0 median citations86% since 2021mostly empirical
Microbiome and transcriptome advancements newly emerged at 15 papers each as Gene research scaled from 2 to 40 papers.
rising sub-themes (early→recent)
- Gene2→40
- Fermentation1→12
- Antimicrobial1→9
- Population1→9
- Agriculture1→8
Newly emergingMicrobiome 0→15 · Transcriptome 0→15 · Metagenomics 0→10
Landmark Lignin Valorization: Improving Lignin Processing in the Biorefinery · 3,958 cites
▼
Concerns164 · 17%
▼ 22%→14% share
▼0.6× share momentum0 median citations71% since 2021mostly reviews
Antibiotic resistance and agriculture concerns are intensifying — both rose from 3 to 10 papers as the segment's field-share cooled from 22% to 14%.
rising sub-themes (early→recent)
- Agriculture3→10
- Antibiotic resistance3→10
- Antimicrobial1→6
- Human health2→7
- Microbiome2→6
Newly emergingContext (archaeology) 0→8 · Resistance (ecology) 0→6 · Gene 0→6
Landmark The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate · 8,812 cites
RESEARCH HOTSPOTS · Canada
Where biotechnology is researched across Canada
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Montreal99 · +0.45
Edmonton/Calgary71 · +0.39
Toronto63 · +0.49
Vancouver61 · +0.40
Ottawa/Kingston34 · +0.40
Waterloo/Hamilton31 · +0.41
PATENT SIGNAL · Canada
Who's filing biotechnology patents in Canada
Canada biotechnology patent filing is accelerating — 18,553 filings from 8,000 assignees (2016–2025), led by UNIV British Columbia, UNIV Health Network, NAT RES Council Canada; annual filings 1716→1734.
18,553 filings8,000 assigneespeak 2082/yr2016–2025
filing momentum (YoY 2016–2025)
top patent filers
- UNIV British Columbia1570
- UNIV Health Network1208
- NAT RES Council Canada900
- UNIV Alberta753
- CA NAT Research Council699
- Medicago680
- UNIV Saskatchewan597
- Zymeworks594
Common questions
How many Life Sciences companies are there in British Columbia, Canada?
Radar tracks 305 indexable Life Sciences companies headquartered in British Columbia, Canada that meet our profile-completeness bar.
What is the total funding raised by Life Sciences companies in British Columbia, Canada?
The Life Sciences companies in British Columbia, Canada on this list have raised a combined $3B in disclosed equity funding across 130 funded companies.
Which is the highest-funded Life Sciences company in British Columbia, Canada?
Novelion Therapeutics is the highest-funded Life Sciences company in British Columbia, Canada, with $325M in disclosed equity funding.
How many Life Sciences companies in British Columbia, Canada are funded?
130 of the 305 Life Sciences companies in British Columbia, Canada on this list have disclosed at least one equity funding round.
How many Life Sciences unicorns are there in British Columbia, Canada?
None of the Life Sciences companies in British Columbia, Canada on this list currently has a disclosed valuation of $1B or more.
Who are the top investors in British Columbia, Canada Life Sciences companies?
The most active investors in British Columbia, Canada Life Sciences companies on this list include WUTIF Capital, BDC, E-Fund, adMare BioInnovations, Cascadia Venture Forum.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.